WeVote
Log In

Bill

Bill

AJR 161

Establishes New Jersey Pancreatic Cancer Commission.

2026-2027 Regular Session Introduced by Shanique Speight

New Jersey legislation creates a Pancreatic Cancer Commission to coordinate research, education, and treatment efforts across the state.

Introduced, Referred to Assembly Health Committee
0
WeVote Research Nonpartisan
Bill Summary · AJR 161

Legislative bill overview

AJR 161 establishes a New Jersey Pancreatic Cancer Commission to coordinate research, prevention, education, and treatment efforts related to pancreatic cancer within the state. The commission would likely bring together medical professionals, researchers, and patient advocates to develop comprehensive strategies addressing this disease.

Why is this important

Pancreatic cancer has one of the lowest survival rates among major cancers, making coordinated state-level efforts potentially valuable for improving outcomes. The commission could facilitate knowledge-sharing between institutions, identify gaps in care and research, and raise public awareness about risk factors and screening in New Jersey.

Potential points of contention

  • Cost and funding: No details provided on how the commission would be funded or what operating budget would be required from the state
  • Scope and authority: Unclear what actual powers the commission would have versus serving as an advisory body, and whether it duplicates existing efforts by hospitals, universities, or cancer organizations
  • Resource allocation: Questions about whether establishing a disease-specific commission sets precedent for similar commissions for other cancers or health conditions, raising equity concerns about prioritization

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.